Invivogen
Menu

Anti-CD20 (Rituximab biosimilar - IgG1 isotype)

Product Unit size Cat. code Docs. Qty. Price

Anti-hCD20-hIgG1

Human CD20 (Rituximab) antibody - Human IgG1

Show product

100 µg

3 x 100 µg

1 mg

hcd20-mab1
+-
$109
  • About
  • Specifications
  • Contents
  • Related products

Human IgG1 monoclonal antibody (mAb) against human CD20

Effector functions of mAb isotypes targeting CD20

Anti-hCD20-hIgG1 is the biosimilar of the clinical antibody rituximab. Anti-hCD20-hIgG1 features the constant region of a human IgG1 isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the human CD20 antigen found on the surface of malignant and normal B lymphocytes.

The binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation, and cell-mediated cytotoxicity.

Rituximab has been approved by the FDA to treat various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.

Anti-hCD20-hIgG1 was generated by recombinant DNA technology. It has been produced in Chinese hamster ovary (CHO) cells and purified by affinity chromatography with protein G.

More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see below or in the 'upon request' section). InvivoGen also provides type I and type II anti-hCD20 mAbs featuring the variable regions of Ofatumumab or Obinutuzumab, with either native or engineered Fc regions.

Figures

ADCC assay using various anti-human CD20 (Rituximab) antibody isotypes and Raji-Null target cells
ADCC assay using various anti-human CD20 (Rituximab) antibody isotypes and Raji-Null target cells

Comparison of ADCC potency for native and engineered anti-human CD20 antibody isotypes: Raji-Null cells were incubated with gradient concentrations of Anti-hCD20 or Anti-β-galactosidase (β-gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with targets cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown

Back to the top

Specifications

Target: Human CD20

Clonality: Monoclonal antibody

Clone: Rituximab (Anti-hCD20-hIgG1, kappa)

Isotype: Human IgG1, kappa

Control: Human IgG1

Source: CHO cells

Formulation: 0.2 µm filtered solution in 68 mM sodium phosphate buffer (pH 7.4) with 91 mM glycine, 5% w/v saccharose, and stabilizing agents

Purity: Purified by affinity chromatography with protein G

Tested application: Flow cytometry and ADCC

Quality control:

  • Binding of Anti-hCD20-hIgG1 to human CD20 has been tested using flow cytometry.
  • The complete sequence of this antibody has been verified.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top

Contents

Anti-hCD20-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

  • hcd20-mab1: 100 µg
  • hcd20-mab1-03: 3 x 100 µg
  • hcd20-mab-1: 1 mg

 The product is shipped at room temperature.

 Upon receipt, store lyophilized antibody at -20°C.

 

 

Tags: buy Rituximab (anti-CD20) | Rituximab (anti-CD20) supplier | purchase Rituximab (anti-CD20) | Rituximab (anti-CD20) cost | Rituximab (anti-CD20) manufacturer | order Rituximab (anti-CD20) | Rituximab (anti-CD20) distributor

Back to the top
Customer Service
& Technical Support
Shopping cart is empty